AMO Pharma Limited: AMO Pharma Announces Completion of Treatment of Last Patient in Pivotal REACH-CDM Clinical Trial in Myotonic Dystrophy

Company on track to present first data from REACH-CDM trial in July 2023. LONDON, April 25, 2023 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company

Related Keywords

United Kingdom ,London ,City Of ,New Zealand ,Australia ,Canada ,Ibs Mahmood ,Nicholas Johnson ,Caitlin Oreilly ,Commission On Human Medicines ,Virginia Commonwealth University School Of Medicine ,Drug Developers ,Berry Company Public Relations ,Department Of Neurology ,Myotonic Dystrophy Foundation On ,Pharma Limited ,Chief Executive Officer ,Virginia Commonwealth University School ,Principal Investigator ,Myotonic Dystrophy Foundation ,Human Medicines ,Pharma ,Imited ,Nnounces ,Completion ,Treatment ,Mast ,Patient ,Pivotal ,Peach ,Linical ,Trial ,Myotonic ,Dystrophy ,